TY - JOUR
T1 - Botulinum toxin type a in children and adolescents with severe cerebral palsy
T2 - A retrospective chart review
AU - Mesterman, Ronit
AU - Gorter, Jan Willem
AU - Harvey, Adrienne
AU - Lockhart, Julia
AU - McEwen-Hill, Jenny
AU - Margallo, Karen
AU - Goldie, Nancy
PY - 2014/2/1
Y1 - 2014/2/1
N2 - This retrospective cohort study reviewed set goals and their outcomes of children and adolescents with severe cerebral palsy who received botulinum toxin A in 2008 and 2009. Sixty children (36 male, mean age 9 years) were included. They received on average 4 (range 1-7) treatments, with the dosage varying between 20 and 400 units per treatment (3-21 U/kg/body weight). Mild transient side effects were reported in 12 of 242 treatments with botulinum toxin A. Treatment goals were related to lower limb function (82%), range of motion (68%), positioning (33%), upper limb function (33%), and facilitating ease of care in dressing (30%), toileting, and diapering (22%). The treatment goals were reached in 60% to 85% by report of the parent and child dyad. Our findings suggest that botulinum toxin A should be considered as a treatment option in patients with cerebral palsy within Gross Motor Function Classification System levels IV and V.
AB - This retrospective cohort study reviewed set goals and their outcomes of children and adolescents with severe cerebral palsy who received botulinum toxin A in 2008 and 2009. Sixty children (36 male, mean age 9 years) were included. They received on average 4 (range 1-7) treatments, with the dosage varying between 20 and 400 units per treatment (3-21 U/kg/body weight). Mild transient side effects were reported in 12 of 242 treatments with botulinum toxin A. Treatment goals were related to lower limb function (82%), range of motion (68%), positioning (33%), upper limb function (33%), and facilitating ease of care in dressing (30%), toileting, and diapering (22%). The treatment goals were reached in 60% to 85% by report of the parent and child dyad. Our findings suggest that botulinum toxin A should be considered as a treatment option in patients with cerebral palsy within Gross Motor Function Classification System levels IV and V.
KW - botulinum toxin A
KW - cerebral palsy
KW - children
KW - hypertonia treatment
KW - outcome
UR - http://www.scopus.com/inward/record.url?scp=84892759020&partnerID=8YFLogxK
U2 - 10.1177/0883073813495306
DO - 10.1177/0883073813495306
M3 - Review Article
C2 - 23965398
AN - SCOPUS:84892759020
SN - 0883-0738
VL - 29
SP - 210
EP - 213
JO - Journal of Child Neurology
JF - Journal of Child Neurology
IS - 2
ER -